What smart money is saying about Novo Nordisk A/S
9 funds in our archive have pitched Novo Nordisk A/S — most recently Schafer Cullen International High Dividend ADR in December 2025.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Fund coverage · 9 theses
- Schafer Cullen International High Dividend ADRDecember 2025
Novo Nordisk is a metabolic health leader with durable GLP-1 advantages, expanding access and an oral launch supported by manufacturing scale and long-term platform growth at an attractive valuation and yield.
Read the full thesis - Vltava FundSeptember 2025
Novo Nordisk is a leading global company in diabetes and obesity treatment, experiencing a recent share price decline despite significant growth potential in the obesity market, making it an attractive long-term investment opportunity.
Read the full thesis - Loomis Sayles International Growth FundSeptember 2025
Novo is expected to sustain its leading position in the rapidly growing GLP-1 market through continued innovation and optimization of pricing and supply strategies, despite competitive pressures.
Read the full thesis - Protean FundsJune 2025
Novo Nordisk faces shrinking market expectations, intensifying competition, and leadership uncertainty, prompting a cautious stance despite potential upside from new markets, pipeline opportunities, and attractive valuations. Demander à ChatGPT
Read the full thesis - Protean FundsJune 2025
Novo Nordisk is a compelling investment opportunity due to its strong market position, favorable valuation, and positive developments under new leadership, despite ongoing uncertainties.
Read the full thesis - Mayar CapitalMarch 2025
Novo Nordisk is a leading Danish pharmaceutical company specializing in diabetes care and obesity treatments, well-positioned for sustainable growth with its innovative GLP-1 drugs and diverse pipeline.
Read the full thesis - Loomis Sayles International Growth FundMarch 2025
Novo Nordisk is poised for long-term success in the rapidly growing GLP-1 market, maintaining its leadership through innovation and strong demand despite near-term pressures.
Read the full thesis - Clearbridge Large Cap Value StrategyMarch 2025
Novo Nordisk is well-positioned to capitalize on the vast GLP-1 diabetes and obesity drug market despite recent stock fluctuations.
Read the full thesis - Loomis Sayles International Growth FundDecember 2024
Novo is well-positioned to sustain its competitive edge in the rapidly growing GLP-1 market, with strong product differentiation and ongoing innovation driving double-digit revenue growth amidst rising competition.
Read the full thesis
Read every full thesis on Novo Nordisk A/S
Unlock all 9 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→